40,000 bottles of eye drops across the US recalled over issues with sterility of product

Major US Retailers Pull Eye Drop Product After Sterility Concerns Trigger FDA Recall

Wanderstayfinder.com – Shoppers at grocery chains, discount stores, and big-box retailers across the United States are being told to set aside a popular over-the-counter eye drop product and seek a full refund. The Food and Drug Administration confirmed on 22 August 2026 that approximately 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief are being withdrawn from circulation after the manufacturer could not guarantee that every unit remained sterile through its shelf life.

The recall was initiated voluntarily by Prestige Brand Holdings, a company headquartered in Tarrytown, New York. In its enforcement report, the FDA cited the company’s own admission of a

“lack of assurance of sterility”

as the basis for pulling the product from the market. No consumer illness or injury has been publicly linked to this particular lot, but regulators judged the uncertainty significant enough to warrant immediate action.

What Exactly Is Being Recalled

The affected units are 15-millilitre bottles bearing lot code 2552A and an expiration date of 30 September 2027. They were distributed nationally through Medtech Products Inc, a subsidiary of Prestige Consumer Healthcare. The product is formulated as an astringent and lubricant combination intended to ease redness, itching, burning, and watery eyes. Its packaging markets it under the Clear Eyes brand name as a maximum-strength itch-relief formula.

Because the eye drops passed through multiple retail channels, consumers at Walmart, Target, Kroger, Giant Eagle, Meijer, Dollar General, and Family Dollar locations may still find unopened bottles on shelves. The FDA’s guidance is straightforward: stop using any bottle matching the lot code above and return it to the point of purchase for a refund. Those who have already used the product and worry about possible irritation or infection should speak with a pharmacist or their primary-care provider.

Understanding the FDA’s Risk Classification

The agency assigned this action a Class II designation. On the FDA’s own website, a Class II recall describes a moderate-risk scenario in which

“use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”

In practical terms, that means regulators do not believe the product is likely to cause permanent damage, but they also cannot rule out short-term complications such as conjunctivitis, corneal irritation, or a mild bacterial infection introduced by a non-sterile solution. For a product applied directly to the eye’s surface, even a small probability of contamination warrants prompt removal.

Why Sterility Matters for Ophthalmic Products

Unlike topical creams applied to intact skin, eye drops bypass the body’s primary physical barriers. The conjunctiva and cornea are thin, highly vascularised tissues with limited immune defences. A single colony of bacteria or fungal spore in a dropper bottle can multiply rapidly at body temperature, turning a routine dose into an infection that may require antibiotic drops, steroid therapy, or in extreme cases surgical intervention. This is why the FDA treats sterility assurance as a non-negotiable quality attribute for every ophthalmic preparation sold in the United States, whether prescription or over-the-counter.

A Broader Context: Eye Drop Recalls in an Era of Food-Safety Strain

Recalls of ophthalmic products remain comparatively rare in the American marketplace. Over the past several years, the FDA’s enforcement resources have been heavily consumed by a sustained food-safety crisis. Under the current administration, the country has been dealing with one of the largest recorded foodborne-illness outbreaks in its history, stretching public-health infrastructure thin and drawing regulatory attention away from smaller product categories.

That does not mean eye drops are risk-free. The most consequential ophthalmic recall in recent memory occurred in 2023, when the FDA pulled EzriCare Artificial Tears after laboratory testing linked the product to an outbreak of Pseudomonas aeruginosa, a bacterium notorious for developing resistance to common antibiotics. The contamination event was associated with at least one death and illness in 68 additional individuals. A small subset of those patients required surgical removal of the affected eye, underscoring how quickly a contaminated ophthalmic product can escalate from mild irritation to sight-threatening or life-threatening infection.

What Consumers Should Do Now

If you own a bottle of Clear Eyes Maximum Itchy Eye Relief, check the bottom or side of the container for lot code 2552A and an expiry of 30 September 2027. If both match, discontinue use immediately. Return the bottle to the store where it was purchased, or contact the manufacturer’s consumer line for a mail-in refund. Do not attempt to “finish” a partially used bottle; the sterility question applies to every drop remaining in the container.

For those who rely on over-the-counter eye drops for chronic dryness, allergies, or post-surgical comfort, the recall is a reminder to verify lot numbers periodically and to report any unusual stinging, persistent redness, or discharge to a clinician promptly. The eye’s fragility leaves little margin for error, and early intervention remains the single most effective safeguard against the complications that make sterility failures so consequential.